Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.